

| | | | | | |
|---|---|----|---|--------------------------|------------------|
| IDS Form PTO/SB/08: Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/579,357 |
| | | | | Filing Date | May 16, 2006 |
| | | | | First Named Inventor | Reinhard BOLLI |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | Yunsoo KIM |
| Sheet | 1 | of | 4 | Attorney Docket Number | 06478.1507-00000 |

| U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS | | | | | |
|---|-------------|-----------------------------|--|--|---|
| Examiner Initials | Cite No. | Document Number | Issue or Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code (if known) | | | |
| | 10 | 4,396,608 | 08-02-1983 | Tenold | |
| | 11 | 4,439,421 | 03-27-1984 | Hooper et al. | |
| | 12 | 4,499,073 | 02-12-1985 | Tenold | |
| | 13 | 4,849,508 | 07-18-1989 | Magnin et al. | |
| | 14 | 4,880,913 | 11-14-1989 | Doleschel et al. | |
| | 15 | 5,164,487 | 11-17-1992 | Kothe et al. | |
| | 16 | 5,177,194 | 01-05-1993 | Sarno et al. | |
| | 17 | 5,593,675 | 01-14-1997 | Hodler, et al. | |
| | 18 | 6,069,236 | 05-30-2000 | Burmouf-Radosevich et al. | |
| | 19 | 6,162,904 | 12-19-2000 | Mamidi et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|----------|--|--------------------------------|--|---|---------------------|
| Examiner Initials | Cite No. | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Translation |
| | | Country Code Number Kind Code (if known) | | | | |
| | 20 | DE 2 364 792 | 07-18-1974 | South African Inventions Development Corp. | | English abstract |
| | 21 | DE 3 430 320 A1 | 03-28-1985 | Nihon Seiyaku Co., Ltd. | | English abstract |
| | 22 | DE 4 118 912 C1 | 07-02-1992 | Biotest Pharma GmbH | | English abstract |
| | 23 | EP 0 447 585 B1 | 05-03-1995 | Biotest Pharma GmbH | | English counterpart |
| | 24 | EP 0 893 450 A1 | 01-27-1999 | Bayer Corporation | | |
| | 25 | EP 0 911 037 A1 | 04-28-1999 | Yoshitomi Pharmaceutical Industries, Ltd. | | |
| | 26 | EP 1 084 147 B1 | 09-29-2004 | Statens Serum Institut | | |
| | 27 | EP 1 268 551 B1 | 02-25-2004 | Amersham Biosciences AB | | |
| | 28 | WO 94/29334 | 12-22-1994 | Association Pour L'Esson De La Transfusion Sanguine Dans La Region Du Nord | | English counterpart |

| | |
|-----------------------|--------------------|
| Examiner Signature | Date Considered |
|-----------------------|--------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/579,357 |
| Filing Date | May 16, 2006 |
| First Named Inventor | Reinhard BOLLJ |
| Art Unit | 1644 |
| Examiner Name | Yunsoo KIM |
| Attorney Docket Number | 06478.1507-00000 |

| | | | |
|-------|---|----|---|
| Sheet | 2 | of | 4 |
|-------|---|----|---|

FOREIGN PATENT DOCUMENTS

| | | | | | |
|----|-------------|------------|-------------------------------------|--|--|
| 29 | WO 96/15153 | 05-23-1996 | Baxter International Inc. et al. | | |
| 30 | WO 98/05686 | 02-12-1998 | CSL Limited | | |
| 31 | WO 99/64462 | 12-16-1999 | Statens Serum Institut | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation |
|----------------------|-------------|--|-------------|
| | 32 | Andersson, I. et al., "An Improved Chromatography Method For Production Of IgG From Human Plasma," Presented at XXIII Congress of the International Society of Blood Transfusion (1994). | |
| | 33 | Azulay, J.-P. et al., "Intravenous Immunoglobulin Treatment In Patients With Motor Neuron Syndromes Associated With Anti-GM1 Antibodies, A Double-Blind, Placebo-Controlled Study," Neurology, Vol. 44, pp. 429-432 (1994). | |
| | 34 | Basta, M. et al., "High-Dose Intravenous Immunoglobulin Exerts its Beneficial Effect in Patients with Dermatomyositis by Blocking Endomysial Deposition of Activated Complement Fragments," The Journal of Clinical Investigation Inc., Vol. 94, pp. 1729-1735 (1994). | |
| | 35 | Berkman, S.A. et al., "Clinical Uses of Intravenous Immunoglobulins," Annals of Internal Medicine, Vol. 112, pp. 278- 292 (1990). | |
| | 36 | Biesert L., "Virus Validation Studies of Immunoglobulin Preparations," Clinical and Experimental Rheumatology, Vol. 14, Suppl. 15, pp. S47-S52 (1996). | |
| | 37 | Bjorkander, J. et al., "1040 Prophylactic Infusions with an Unmodified Intravenous Immunoglobulin Product Causing Few Side-Effects in Patients with Antibody Deficiency Syndromes," Infection Vol. 13, No. 3, pp. 102-110 (1985). | |
| | 38 | Brenner, B., "Clinical Experience With Octagam, A Solvent Detergent (SD) Virus Inactivated Intravenous Gammaglobulin," Clinical and Experimental Rheumatology, Vol. 14, Suppl. 15, pp. S115-S119 (1996). | |
| | 39 | Buckley, R.H. et al., "The Use of Intravenous Immune Globulin in Immunodeficiency Diseases," The New England Journal of Medicine, Vol. 325, No. 2, pp. 110-117 (1991). | |
| | 40 | Cassulis, P. et al., "Ligand Affinity Chromatographic Separation of Serum IgG on Recombinant Protein G-Silica," Clin. Chem., Vol. 37, No. 6, pp. 882-886 (1991). | |
| | 41 | Clerc, M.-F. et al., "Labelling of Colloidal Gold with IgE," Histochemistry, Vol. 89, pp. 343-349 (1988). | |
| | 42 | Cooperative Group For the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, "Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic Leukemia, A Randomized, Controlled Clinical Trial," The New England Journal of Medicine, Vol. 319, pp. 902-907 (1998). | |

| | |
|-----------------------|--------------------|
| Examiner Signature | Date Considered |
|-----------------------|--------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | | | | | |
|-------|---|----|---|------------------------|------------------|
| Sheet | 3 | of | 4 | Application Number | 10/579,357 |
| | | | | Filing Date | May 16, 2006 |
| | | | | First Named Inventor | Reinhard BOLLI |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | Yunsoo KIM |
| | | | | Attorney Docket Number | 06478.1507-00000 |

NON PATENT LITERATURE DOCUMENTS

| | | |
|----|--|------------------------|
| 43 | Dalakas, M.C., "Intravenous Immune Globulin Therapy for Neurologic Diseases, Annals of Internal Medicine," Annals of Internal Medicine, Vol. 126, No. 9, pp. 721-730 (1997). | |
| 44 | Dwyer, J.M., "Manipulating the Immune System with Immune Globulin," The New England Journal of Medicine, Vol. 326, No. 2, pp. 107-116 (1992). | |
| 45 | El Alaoui, S. et al., "Development of an Immunocapture Method for Measuring IgA Antibodies to Tissue Transglutaminase in the Sera of Patients with Coeliac Disease," Clinical and Experimental Immunology, Vol. 144, pp. 101-109 (2006). | |
| 46 | Gammagard S/D, "Humanes Immunglobulin Zur Intravenosen Anwendung Solvent/Detergent Behandelt," Product Information, Baxter Deutschland GmbH, Edisonstr. 3-4, D-85716 Unterschleißheim, Germany (1994). | Statement of Relevance |
| 47 | Habeeb A.F.S.A. et al., "Preparation of Human Immunoglobulin by Caprylic Acid Precipitation," Preparative Biochemistry, Vol. 4, No. 1, pp. 1-17 (1984). | |
| 48 | Hansen P. et al., "Isolation and Purification of Immunoglobulins from Chicken Eggs Using Thiolphilic Interaction Chromatography," J. Immunological Methods, Vol. 215, pp. 1-7 (1998). | |
| 49 | Harris, J.R., Ed., "Blood Separation and Plasma Fractionation," pp. 332-333, Wiley-Liss, New York (1991). | |
| 50 | Hocini H. et al., "An ELISA Method to Measure Total and Specific Human Secretory IgA Subclasses Based on Selective Degradation by IgA1-Protease," J. Immunological Methods, Vol. 235, No. 1-2, pp. 53-60 (2000) (Abstract). | |
| 51 | Kaveri, S.-V. et al., "Intravenous Immunoglobulins (IVIg) In The Treatment Of Autoimmune Diseases," Clin Exp. Immunol., Vol. 86, pp. 192-198 (1991). | |
| 52 | Koopman W.J. et al., "A Sensitive Radioimmunoassay for Quantitation of IgM Rheumatoid Factor," Arthritis and Rheumatism, Vol. 23, No. 3, pp. 302-308 (1980). | |
| 53 | Lundblad, J.L. et al., "Comparative Studies of Impurities in Intravenous Immunoglobulin Preparations," The University of Chicago, Reviews of Infectious Diseases, Vol. 8, Supp. 4, pp. S382-S390 (1986). | |
| 54 | McCue, J.P., "Changes in Therapeutic Proteins Caused by Preparation Techniques," Annals of Internal Medicine, Vol. 111, No. 4, pp. 271-272 (1989). | |
| 55 | Mollnes, T.E. et al., "Effect of Whole and Fractionated Intravenous Immunoglobulin on Complement In Vitro," Molecular Immunology, Vol. 34, No. 10, pp. 719-729 (1997). | |
| 56 | Nourichafi, N. et al., "Comparison of various chromatographic supports for purifying human plasmatic immunoglobulins from Cohn II + III fraction," Biotechnology of Blood Proteins, Vol. 227, pp. 207-212 (1993). | |
| 57 | Nydegger, U.E., "Sepsis and Polyspecific Intravenous Immunoglobulins," Journal of Clinical Apheresis, Vol. 12, pp. 93-99 (1997). | |
| 58 | Oldham, G. et al., "A Quantitative Method for Measuring in vitro Synthesis of IgA and IgG by Human Rectal Mucosa: Studies on normal controls and patients with hypogammaglobulinaemia," Immunology, Vol. 37, pp. 661-668 (1979). | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/579,357 |
| Filing Date | May 16, 2006 |
| First Named Inventor | Reinhard BOLLI |
| Art Unit | 1644 |
| Examiner Name | Yunsoo KIM |
| Attorney Docket Number | 06478.1507-00000 |

Sheet

4

of

4

NON PATENT LITERATURE DOCUMENTS

| | | |
|----|---|--|
| 59 | Scopes, R.K., "Protein Purification, Principles and Practice," 2nd Edition, pp. 42-45, published in "Springer Advance Texts In Chemistry," series editor Charles R. Cantor, Springer-Verlag, N.Y. (1987). | |
| 60 | Stucki, M. et. al., "Characterisation Of A Chromatographically Produced Anti-D Immunoglobulin Product," Journal of Chromatograph B., Vol. 700, pp. 241-248 (1997). | |
| 61 | Waldo, F.B. et al., "Mixed IgA-IgG Aggregates As A Model Of Immune Complexes In IgA Nephropathy," The Journal of Immunology, Vol. 142, No. 11, pp. 3841-3846 (1989). | |
| 62 | Wang, W., "Antibody Structure, Instability, and Formulation," Journal of Pharmaceutical Sciences, Vol. 96, No. 1, pp. 1-26 (2007). | |
| 63 | Wells, J.V. et al., "Cord Serum IgA Levels in Australian Infants," J. Paediatrics and Child Health, Vol. 16, No. 3, pp. 189-90 (1980) (Abstract). | |
| 64 | English Language Derwent abstract of DE 2 364 792. | |
| 65 | English Language Derwent abstract of DE 3 430 320 A1. | |
| 66 | English Language Derwent abstract of DE 4 118 912 C1. | |

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.